Changing lifestyle is becoming a major cause of depression.
The initial results of genetic testing are encouraging.
Genetic Testing: Rapidly changing lifestyle and cut-throat competition has made people increasingly prone to depression. Patients suffering from depression have increased significantly in the last few decades. Continuous studies are being done to get people out of depression. A recent study by the US Department of Veterans Affairs states that anti-depression medication can be avoided by pharmacogenomic testing. Let us tell you that many times unwanted results are also seen in patients with end-depression medication.
Know what is Pharmacogenomics
Pharmacogenomics is the study of how our genes are responding to medicines. The results of this new study have also recently been published in the Journal of the American Medical Association. During the study, researchers also found that the results of patients who have been given genetic testing, have got better results than patients with normal care. Patients were treated for 24 weeks during the study, with a reduction in depression symptoms after 12 weeks in the genetic testing group.
All the patients included in the study had severe depressive disorder. These included symptoms such as insomnia, loss of appetite, feeling sad and sad, and suicidal thoughts. According to Dr. David Oslin, director of the Mental Illness, Research, Education and Clinic Center (MIRECC), who led this study, the results of the study will inspire everyone to take pharmacogenomic testing. This testing, which is done with the permission of the patients, will also help in deciding what kind of treatment to give.
Used commercial battery of jeans
Dr. David Oslin and his team used a commercial battery of genes that focused on the CYP450 system. This battery used to test 8 genes, out of which 6 tests were for variants of liver enzymes. What do genes have to do with anti-depressants? On this question, Oslin says, ‘The genes we tested were not really related to depression. We have related to how the person metabolizes the medicine after it enters the body. Some of these genes metabolize the drug faster than normal. On the other hand, others metabolize drugs at a slower rate than normal, this simply means that there is a lot of medicine in the body.
Dr. David Oslin says that during this study there was a significant change in keeping away from the drug-specific drug-gene interaction or moderate drug-gene interaction. 59 percent of the patients were treated without predicting any drug-gene interaction, compared to 26 percent of the control group in the genetic testing group. According to the researchers, a ‘statistically significant and clinically meaningful’ difference was found during this period.